Latest News

Bill makes most up-to-date cancer treatment available to patients; requires fair payment policy for hospitals

New Market Opportunity Analysis and forecast to 2018 prepared by GlobalData highlights Visonac photodynamic therapy for acne as one of the anticipated new product launches that will drive the expansion within the acne market.

Bladder Cancer Advocacy Network urging Congress to enact legislation to secure access to Blue Light Cystoscopy with Cysview

German Institute for Quality and Efficacy in Health Care (IQWiG) confirms benefit of human papilloma-virus (HPV) testing for preventing cervical cancer.

Oslo, Norway, 7 May 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the first quarter 2014.

FDA approves first HPV test for primary cervical cancer screening

FDA advisory committee recommends Roche's HPV test for primary screening of cervical cancer.

Oslo, Norway, 27 February 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the fourth quarter and full year of 2013.

Novel treatment for moderate to severe acne

Oslo, Norway, 23 October 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the third quarter and first nine months of 2013.

Diagnosis and management of non-muscle invasive bladder cancer: How to reach excellence!

22. Jahrestagung der Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie, 26.-28. September 2013

Oslo, Norway, 22 August 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the second quarter and first half 2013.